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AtovaquoneAtovaquone is a substituted 2-hydroxy-naphthoquinone used therapeutically against Plasmodium falciparum
(malaria) and Pneumocystis pathogens. It acts by inhibiting the cytochrome bc1 complex via interactionswith the
Rieske iron–sulfur protein and cytochrome b in the ubiquinol oxidation pocket. As the targeted pathogens have
developed resistance to this drug there is an urgent need for new alternatives. To better understand the
determinants of inhibitor binding in the ubiquinol oxidation pocket of the bc1 complexwe synthesized a series of
hydroxy-naphthoquinones bearing a methyl group on the benzene ring that is predicted to interact with the
nuclear encoded Rieske iron–sulfur protein. We have also attempted to overcome the metabolic instability of a
potent cytochrome bc1 complex inhibitor, a 2-hydroxy-naphthoquinone with a branched side chain, by
ﬂuorinating the terminal methyl group. We have tested these new 2-hydroxy-naphthoquinones against yeast
and bovine cytochrome bc1 complexes to model the interaction with pathogen and human enzymes and
determineparameters that affect efﬁcacyof bindingof these inhibitors.We identiﬁedahydroxy-naphthoquinone
with a triﬂuoromethyl function that has potential for development as an anti-fungal and anti-parasitic
therapeutic.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Malarone is a combination of atovaquone (2-[trans-4-(4′-chlor-
ophenyl) cyclohexyl]-3-hydroxy-1,4-hydroxy-naphthoquinone; ato-
vaquone, Fig. 1A) and proguanil that is used therapeutically against
Plasmodium falciparum (malaria) and Pneumocystis pathogens [1].
Atovaquone inhibits parasite and fungal respiration by speciﬁcally
targeting the cytochrome bc1 complex. It is a competitive inhibitor of
ubiquinol oxidation that acts at center P of the bc1 complex and locks
the iron–sulfur protein in a conformation proximal to cytochrome b,
preventing electron transfer to cytochrome c1 [2,3]. The recent failure
of atovaquone treatment has been linked to mutation of amino acids
located in or near the atovaquone-binding site on cytochrome b [1,4].
Most of the reported mutations in cytochrome b destabilize
important hydrophobic interactions between atovaquone and the
binding domain on the protein or change the volume of the pocket
[5,6]. Since these mutations occur in the mitochondrially encoded
gene for cytochrome b it would be advantageous to target the nuclear
encoded subunit of the binding pocket, the Rieske Fe–S protein [7],
since mutations arise spontaneously at a much lower frequency inthiazole; NQ, naphthoquinone
rumpower).
ll rights reserved.nuclear compared to mitochondrial genes. Earlier modeling studies
have indicated that van der Waals interactions between this subunit
and the inhibitor are improved when the benzene ring of the 2-
hydroxy-naphthoquinone has an alkyl substituent. In order to probe
binding determinants located in the Rieske protein we synthesized a
series of NQs featuring a methyl group on the aromatic ring.
S-10576 is a 2-hydroxy-naphthoquinone that is structurally
similar to atovaquone (Fig. 1B) and that also targets the cytochrome
bc1 complex [7]. However, studies designed to test the therapeutic
potential of S-10576 in vivo showed that the terminal two carbons of
the side chain are modiﬁed by oxidation and the resulting more water
soluble compound is rapidly excreted [8,9]. In the present study we
sought to improve the metabolic stability of S-10576 by ﬂuorinating
the side chain, an increasingly common strategy for ﬁne-tuning the
pharmacological properties of drugs [10]. As atovaquone also inhibits
the yeast bc1 complex, we have developed the yeast Saccharomyces
cerevisiae as a model to probe binding determinants at center P of the
bc1 complex.
We previously designed a model that described the molecular
basis for atovaquone binding in the ubiquinol oxidation pocket of
cytochrome b [2]. Using this model we have compared the binding
afﬁnities of atovaquone, S-10576 and the new hydroxy-naphthoqui-
nones. Comparing the inhibitory activity of these hydroxy-naphtho-
quinones and modeling their interactions with the binding site
provides insight into the structural parameters that affect inhibitor
binding.
Fig. 1. (A) Atovaquone (ATV) (B) S-10576 (C) novel 2-hydroxy-naphthoquinones:
2-OH-3-(2-Me-triﬂuorooctyl)-naphthoquinone (NQ1), 2-OH-3-(2-Me-octyl)-8-Me-
naphthoquinone (NQ2), 2-OH-3-(2-Me-triﬂuorooctyl)-8-Me-naphthoquinone (NQ3).
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2.1. Materials
Atovaquone was a gift from GlaxoSmithKline. The 2-hydroxy-
naphthoquinones were dissolved in dimethyl sulfoxide at 2 mM
concentration and stored at −20 °C.
2.2. Synthesis of naphthoquinones
The hydroxy-naphthoquinones were synthesized as previously
reported [7] via radical alkylation of commercial 2-hydroxy-naphtho-
quinone with alkyl iodides in the presence of tributyltin hydride and
2,2′-azobisisobutyronitrile as radical initiator [11–17]. The synthesis
of the 8-methyl and ﬂuorinated derivatives, mass spectrometry, 1H
and 19F NMR analysis are described in the Supplementary data.
2.3. Puriﬁcation of cytochrome bc1 complexes
Cytochrome bc1 complexes from yeast and bovine heart were
isolated from mitochondrial membranes essentially as described
previously [18,19] with some modiﬁcations. Membranes were solubi-
lized with dodecylmaltoside and diluted to a salt concentration of
100 mMNaClwith 50 mMTris (pH 8.0), 0.02% (w/v) dodecylmaltoside
before anion exchange chromatography. A salt gradient between 100
and 300 mMNaCl in the above detergent was applied. The bc1 enzyme
eluted around 250 mMNaCl and pooled fractions were concentrated to
~0.1–0.3 mM cytochrome bc1 complex by ultraﬁltration (Amicon
Centricon, exclusion limit 100 kDa).
Quantiﬁcation of the bc1 complexwas performed as reported before
[20] by using extinction coefﬁcients of 17.5 mM−1 cm−1 at 553–539 for
cytochrome c1 [21] and 25.6 mM−1 cm−1 at 563–579 for the average
absorbance of the bH and bL hemes in cytochrome b [22].
2.4. Ubiquinol-cytochrome c reductase activity measurements
Cytochrome c reductase activity of puriﬁed cytochrome bc1
complexes were assayed in 50 mM potassium phosphate, pH 7.0,
250 mM sucrose, 0.2 mM EDTA, 1 mMNaN3, 2.5 mMKCN, 0.01% (w/v)
dodecylmaltoside and 40 μMcytochrome c at 23 °C. The cytochromebc1
complex was diluted to 2.5 nM in the assay buffer, inhibitor was added
to the assaymixture and allowed to stirwith the enzyme for 1 min, after
which the reaction was started by adding 2,3-dimethoxy-5-methyl-6-
decyl-1,4-benzoquinol, an analogue of ubiquinol. Reduction of cyto-chrome c was monitored in an Aminco DW-2a spectrophotometer at
550 versus 539 nm in dual wavelength mode. Data were collected and
analyzed using an Online Instrument Systems Inc. computer interface
and software. IC50 values were calculated as the concentration required
to inhibit 50% of the bc1 complex activity compared to untreated
enzyme from titration curves of inhibitor concentration versus activity.
2.5. Pre-steady-state reduction of cytochrome b through center N and
center P
Pre-steady-state reduction of cytochrome bwas followed at 24 °C by
stopped-ﬂow rapid scanning spectroscopy using theOLIS rapid scanning
monochromator as described previously [20]. The oxidant-induced
reduction of cytochrome b through center P was monitored by rapid
mixing of 3 µM cytochrome c with 1 µM bc1 complex pre-reduced by
incubation for 1 min with 30 µM 2,3-dimethoxy-5-methyl-6-decyl-1,4-
benzoquinol before adding 3 µM antimycin and 2 µM NQ1 or 2 µM
atovaquone, and further incubating for 1 min. Cytochrome b reduction
through centerNwasobtainedby rapidmixingof 30 µM2,3-dimethoxy-
5-methyl-6-decyl-1,4-benzoquinol with 1 µM oxidized bc1 complex in
the presence of 3 µM stigmatellin and in the presence and absence of
2 µM NQ1. For each experiment, 12–19 data sets were averaged. The
time course of the absorbance change at 562 and 578 nmwas extracted
using software from OLIS.
2.6. Molecular modeling
Molecular modeling was carried out on Silicon Graphics O2 and
Octane workstations using the commercially available Insight II®
software package (Acclerys Inc., San Diego). The starting structure
was the energy-minimized atovaquone–liganded yeast cytochrome
bc1 complex [2]. Brieﬂy, a minimized conformation of atovaquonewas
docked into a stigmatellin liganded crystal structure [23] that was
modiﬁed to include the rotation of Glu-272 and a water-mediated
hydrogen bond observed in the nHDBT liganded crystal structure [24].
For the structures shown here, the initial docking was achieved by
overlay of the hydroxy-naphthoquinone ring with the one from the
previously calculated atovaquone structure. The initial position of the
linear aliphatic side chain, prior to the molecular dynamics run,
followed the one observed in the nHDBT crystal structure.
The NQs and cytochrome b residues within 4.0 Åwere allowed to be
ﬂexible. A surrounding 9.5 Å shell of residues in both cytochrome b and
the iron–sulfur protein was ﬁxed, and the most distant residues were
excluded from the calculation in order to obtain a manageable
simulation speed. A 9.5 Å atom-based cut-off for non-bonding interac-
tionswas usedduring the calculations,with thedielectric constant set at
2.0. Eight simulated annealing runs were performed, each from 800 to
298K,withﬁve temperature steps anda simulation timeof 5000 fs/step.
The Nose temperature control method was used with a 0.5 fs/iteration
time step. A custom macro was written to select the lowest energy
structure from each dynamics run for continued modeling. Between
each dynamics run, a minimization of 250 iterations was performed.
After theﬁnal roundofmolecular dynamics, the lowest energy structure
was minimized to a ﬁnal convergence criterion of 0.001, using
Cauchycuq's steepest descent method as implemented in the Discover
3® module within the Insight II® software, followed by conjugate
gradient and Newton methods in succession. Of the eight minimized
results obtained, the three lowest energy structures were chosen for
binding energy calculation.
The binding energy calculation was adapted from a previous
method [7] and uses a common subset that included the NQ and
cytochrome b residues within 4.0 Å of the inhibitor. The reported
value for each NQ is an average of the three calculated lowest energy
structures and contains non-bonding interactions (van der Waals and
electrostatic) as well as internal conformational energies of the ligand
and adjacent pocket residues.
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3.1. Inhibition of yeast bc1 complexes by 2-hydroxy-naphthoquinones
The hydroxy-naphthoquinone S-10576 (Fig. 1B) is a potent inhibitor
of the cytochrome bc1 complex [5]. However, although effective against
avian malaria, S-10576 was ineffective in humans due to rapid
metabolic degradation [25]. Toovercome this limitation for thepotential
use of this compound as a therapeuticwe synthesized twoderivatives of
S-10576 (Fig. 1C) bearing a metabolically stable triﬂuoromethyl group
and six with a methyl moiety on the aromatic ring. The methyl
substituent was introduced into the number 8 position on the aromatic
ring on the basis of molecular modeling studies that indicated the
possibility of non-covalent interactions between a methyl group in this
location and the Rieske iron–sulfur protein as shown in Fig. 2. As can be
seen from the ﬁgure, the lowest energy conformation of the bound
ligand positions the 8-methyl group within van der Waals distance of
the sulfur atom of Cys180 of the Rieske protein.
The titration curves in Fig. 3A show the inhibitory activity of the new
agents against cytochrome bc1 complexes puriﬁed from yeast, which
shares a high degree of sequence identity with parasitic enzymes [7]. Of
the S-10576 analogs, the triﬂuorinated NQ1 was the most active,
followed by the 8-methyl substitutedNQ2. The S-10576 derivativewith
both a ﬂuorinated chain and a substituted aromatic ring, NQ3, was the
least active.Fig. 2. Structure of 2-OH-3-(2-Me-octyl)-8-Me-naphthoquinone (NQ2) docked in the ubiqu
shown as gold and cyan ribbons, respectively. Van der Waals radii depicting the non-coval
(C180) of the Rieske protein are shown. The hydrogen bond between the 2-hydroxy grou
between the 4-carbonyl oxygen of NQ2 and Glu-272 of cytochrome b are indicated by dashe
nitrogens are blue, sulfurs are yellow, and iron is purple. The structure was created by subst
[23] and energy minimization as described in the Experimental procedures.A series of naphthoquinones (NQ4-7) featuring a methyl group on
carbon 8 of the aromatic ring and bearing straight alkyl chains of 8 to
11 carbons were compared with an analogous series that have an
unsubstituted carbon 8. The methyl moiety decreased the potency of
the naphthoquinones. Comparison of the IC50 values (Fig. 4) shows
that the optimal chain length is 8 carbons for the NQ series without
the 8-methyl substituent, which is consistent with previous results [4]
and 9 carbons for the 8-methyl substituted derivatives. Addition of the
8-methyl group to the NQ with a 9 carbon side chain increased the
IC50 from 180 nM to 550 nM.3.2. Differential binding of 2-hydroxy-naphthoquinones to bovine and
yeast bc1 complexes
We also assayed NQ1-3 against the bovine bc1 complex to evaluate
the interaction of the inhibitors with the human enzyme, since the
bovine and human cytochrome b sequences are 80% identical [7]. As
shown in Fig. 3B, the triﬂuoromethyl substituted NQ1 was the most
potent inhibitor of the bovine enzyme followed by atovaquone. The 8-
methyl compounds NQ2 and NQ3 were more potent inhibitors of the
bovine enzyme than the parent molecule S-10576. This contrasts with
the relative efﬁcacies of these three inhibitors with the yeast enzyme, in
which case S-10576 was the most potent of these three inhibitors
(Fig. 3A).inol oxidation pocket at center P. Portions of the Rieske protein and cytochrome b are
ent interaction between the 8-methyl group of the naphthoquinone ring and Cys-180
p of NQ2 and His-181 of the Rieske protein and the water-mediated hydrogen bond
d white lines. Carbon atoms are shown in green, oxygens are red, hydrogens are white,
itution of NQ2 into the stigmatellin liganded crystal structure of the yeast bc1 complex
Fig. 3. Effect of 2-hydroxy-naphthoquinones on bc1 activity of (A) yeast and (B) bovine
bc1 complexes. The cytochrome c reductase activity of puriﬁed enzyme was measured
as described in Materials in the presence of increasing concentrations of inhibitor. The
assays were performed in duplicate and the results are shown as averages. Activities are
expressed as a percentage of the turnover number of each strain in the absence of
inhibitor.
Fig. 4. Effect of chain length on inhibition of yeast cytochrome bc1 complexes by 2-
hydroxy-naphthoquinones without and with a methyl group on carbon 8 of the
naphthoquinone ring. The IC50 values for inhibition of the bc1 complex activity are
shown with light gray bars for the 2-hydroxy-3-alkyl-naphthoquinones and dark gray
bars for the 2-hydroxy-3-alkyl-8-methylnaphthoquinones.
Fig. 5. Selectivity of 2-hydroxy-naphthoquinone inhibitors of the bovine and yeast
cytochrome bc1 complexes. The bar graphs show the Selectivity Coefﬁcients for inhibition
of the yeast versus bovine bc1 complex by atovaquone (ATV), S-10576 and its derivatives
2-OH-3-(2-Me-triﬂuorooctyl)-naphthoquinone (NQ1), 2-OH-3-(2-Me-octyl)-8-Me-
naphthoquinone (NQ2), and 2-OH-3-(2-Me-triﬂuorooctyl)-8-Me-naphthoquinone
(NQ3).
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bc1 complexes, we deﬁned the ‘Selectivity Coefﬁcient’ of an inhibitor
as the IC50 obtained with the bovine enzyme divided by the IC50
obtained with the yeast enzyme. The Selectivity Coefﬁcients for
atovaquone, S-10576, NQ1, NQ2 and NQ3 are shown in Fig. 5. S-10576
had the greatest selectivity, which was almost 10 fold greater than
that of atovaquone. Although the selectivity of NQ1, NQ2, and NQ3
were less than that of S-10576, all of the derivatives displayed higher
selectivity than atovaquone.
3.3. Molecular modeling of 2-hydroxy-naphthoquinones docked in the
yeast cytochrome bc1 complex
Although a crystal structure is not available, atovaquone binding
has been modeled using the coordinates of the stigmatellin liganded
yeast enzyme [2]. In a previous study a good correlation was foundbetween relative binding energies of NQs calculated using this model
and their inhibitory activity against cytochrome bc1 complexes [7]. In
the current study the energy required for binding of the NQs was
calculated for each of the modeled structures. The calculated binding
energies were then compared with the experimentally measured IC50
values and are shown in Fig. 6. Overall the difference in calculated
binding energies of compounds NQ1-3 was small. The methyl-
substituted NQ3 had a slightly lower calculated binding energy than
S-10576. However, the most potent inhibitor NQ1 was predicted to
have a higher binding energy than the parent compound. In particular
the angle and torsion components of the binding energy are higher for
NQ1 than S-10576.
3.4. Speciﬁc binding of 2-hydroxy-naphthoquinone inhibitors to center P
of the yeast cytochrome bc1 complex
In order to determine whether NQs bind to center P or N, we
monitored cytochromeb reduction in thepresence of a centerN inhibitor
Fig. 6. Experimentally measured IC50 values compared to calculated binding energies of
S-10576, 2-OH-3-(2-Me-triﬂuorooctyl)-naphthoquinone (NQ1), and 2-OH-3-(2-Me-
triﬂuorooctyl)-8-Me-naphthoquinone (NQ3) in yeast cytochrome bc1 complex. The
IC50 values for the inhibition of the yeast bc1 complex activity are shown in light gray
bars. The dark gray bars show the calculated binding energies.
Fig. 7. Speciﬁc binding of 2-hydroxy-naphthoquinone inhibitors to center P of the yeast
cytochrome bc1 complex. Upon rapid mixing of cytochrome c with bc1 complex that had
beenpartially reduced by incubationwith quinol before the addition of antimycin andNQs
(yielding the initial absorbance shown at t=0), the additional oxidant-induced reduction
of cytochrome b through center P (A)was greatly inhibited by atovaquone (middle trace),
and completely by 2-OH-3-(2-Me-triﬂuorooctyl)-naphthoquinone (NQ1, lower trace). In
contrast, cytochrome b reduction through center N (B) obtained by rapid mixing of 2,3-
dimethoxy-5-methyl-6-decyl-1,4-benzoquinol with oxidized bc1 complex in the presence
of stigmatellin yielded identical, superimposed kinetic traces in the presence and absence
of 2-OH-3-(2-Me-triﬂuorooctyl)-naphthoquinone (NQ1).
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completely inhibited the additional oxidant-induced reduction of
cytochrome b through center P in bc1 complex that had been incubated
with quinol to reduce the Rieske protein (resulting also in partial
cytochrome b reduction) before addition of antimycin and NQs. In
contrast, NQ1 had no effect on cytochrome b reduction through center N
in the presence of stigmatellin (Fig. 7B). If NQ1 or atovaquone were
preincubated with the fully oxidized enzyme before reduction with
quinol, the ﬁrst turnover at center P was not inhibited (results not
shown). This effect of NQs is due to the fact that these inhibitors, like
stigmatellin, bind more tightly to center P when the Rieske protein is
reduced, and thus differ from inhibitors like myxothiazol that do not
interactwith theRieskeprotein andare therefore insensitive to the redox
state of the FeS cluster (see ref. [26] and references therein). The higher
potency of NQ1 relative to atovaquone in inhibiting center P under pre-
steady state conditions (Fig. 7A) agrees with the results obtained under
multi-turnover conditions (see Fig. 3).
4. Discussion
Atovaquone has broad-spectrum activity against species of Plas-
modium, Pneumocystis, Toxoplasma gondii [6] and Babesia spp. [25]. In
the current study we synthesized and screened novel NQs that
featured straight and branched alkyl chains on the quinoid carbon–
carbon double bond and a methyl group on carbon 8 of the aromatic
ring. Modeling studies had indicated that a methyl group on carbon
8 of the aromatic ring of NQ may have favorable van der Waals
interactions with the Rieske Fe–S protein (Fig. 2). However the 8-
methyl derivatives with unbranched alkyl chains are weak cyto-
chrome bc1 complex inhibitors and were not studied further.
Like the hydroxy-naphthoquinone derivatives, stigmatellin binds
center P of the bc1 complex via polar and nonpolar interactions [27]. The
chromone head group is structurally similar to a naphthoquinone and
forms hydrogen bonds with His-161 of the Rieske protein and Glu-272
of cytochrome b. However while the aromatic ring of stigmatellin bears
two methoxy substituents, the introduction of a methyl group into the
benzene ring of NQ caused a signiﬁcant loss in inhibitory activity, which
indicates the high speciﬁcity of the binding pocket for these classes of
inhibitors.
The crystal structure of stigmatellin bound to center P identiﬁed
close (≤4.0 Å) contacts of the protein complex with the ligand [27]. A
comparison of the non-bonding interactions at the binding site of
stigmatellin andNQ1-3 revealed that there are the same8 residues close
to each inhibitor. These non-bonding contacts are distributed along the
alkyl side chains, involvingmostly hydrophobic residues of cytochrome
b transmembrane helices C and F, and the cd1 and ef helices. Thesimilarity of the interaction of stigmatellin and NQs with these residues
highlights the importance of hydrophobic interactions for docking of
ligands into the ubiquinol oxidation pocket of the cytochrome bc1
complex.
Previously we found that there was good agreement between the
experimentally measured changes in IC50 values for inhibition by NQs
and theoretically calculated changes inbindingenergies [7,24]. However
in the present study the changes in binding energies were small and did
not correlate with the IC50 values. This may reﬂect the fact that IC50 is a
free energy (ΔG) term, which includes an entropic parameter, whereas
the calculated binding energy is solely enthalphic (ΔH).
Interestingly, Winter et al. discovered that replacement of the
hydroxy group in NQ by a triﬂuoropentyloxy side chain improved the
anti-malarial potency of the parent compound by over 50 fold [28]. In
addition, haloacridones bearing a terminal CF3 group in the alkoxy
substituent exhibited a profound enhancement in anti-malarial action
against D6 and Dd2 P. falciparum strains. This suggests that CF3 groups
43L.M. Hughes et al. / Biochimica et Biophysica Acta 1797 (2010) 38–43may improve the interactions between the cytochrome bc1 complex
and both acridone and NQ inhibitors.
For high species selectivity, the optimal chain length of the NQs
consisted of 8 carbons. Similarly, Baramee et al. reported that NQs
bearing alkyl chains of 6 to 8 carbons display signiﬁcant anti-parasitic
activity [29]. Fluorination of S-10576 presumably impedes hepatic
P450-mediated oxidation, however it decreased the species selectivity
of the NQ. This may be due to the larger volume of the triﬂuoromethyl
function, estimated as being slightly larger than an isopropyl moiety
[30]. Although the species selectivity of the ﬂuorinated NQ1 was lower
than that of the parent compound S-10576, it was still greater than that
of atovaquone. Moreover, the IC50 of the triﬂuorinated NQ1 was
signiﬁcantly lower than that of atovaquone. This suggests that NQ1 is
a novel inhibitor of the cytochrome bc1 complex with properties that
indicate potential for development as an anti-parasitic and anti-fungal
lead compound. Its speciﬁcity may be improved by substituting a less
bulky side chain such as a monoﬂuorinated 8-carbon chain or a 6 to 7-
carbon chain with a terminal triﬂuoromethyl moiety.
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